Methods, dosing regimens and medications using Anti-progestational agents for the treatment of disorders

Abstract

The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and / or shorter than previously thought possible.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit, under 35 U.S.C. §119, of provisional U.S. Application Ser. No. 60 / 780,047, filed Mar. 8, 2006, the entire contents and substance of which is hereby incorporated by reference.FIELD OF THE INVENTION[0002]The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. The disorders treated can be, but are not limited to, benign gynecological disorders.BACKGROUND OF THE INVENTION[0003]Progesterone plays a major role in reproductive health and functioning. Its effects on, for example, the uterus, breast, cervix and hypothalamic-pituitary unit are well established. It also has extra-reproductive activities that are less well studied, such as effects on the brain, the immune system, the vascular endothelial system and on lipid metabolism. Given this wide ar...

AI Technical Summary

Benefits of technology

[0014]Methods, dosing regimens and medications have now been discovered which provide a means for treating progesterone-related disorders but with a markedly lower dosage level or shorter time period of administration than employed previously. These methods, dosing regimens and medications can treat progesterone-related disorders at doses that avoid or lessen the occurrence or severity of adverse side effects found at higher doses. In one embodiment, the low-dose methods, dosing regimens and medications of the present invention are used to treat uterine leiomyomata.

[0015]Specifically, and in one embodiment, the present invention shows that about 2.5 mg mifepristone provides an effective treatment dosage for progesterone-related disorders. The present invention also shows that about 5.0 mg mifepristone provides an effective treatment dosage for progesterone-related disorders when administered for about one month. These lower dosages and / or shorter time periods of administration can have fewer or less severe side effects and adverse reactions than those observed with previously-used higher doses and / or longer time periods of treatment. Doses as low as 1.0 mg or below can also provide effective treatments for progesterone-related disorders.

[0129]In another embodiment of the non-mifepristone dosing regimens of the present invention, the dosing regimen further directs the administration of a maintenance dose to the patient after the completion of a first round of treatment.

Problems solved by technology

While these tumors are generally benign, they nonetheless can cause a variety of troubling symptoms.

For example, uterine leiomyomata can cause pain in the lower back and abdomen, excessive menstrual bleeding (both in terms of volume and length of menstrual periods or bleeding between menses resulting in anemia and fatigue), pressure on the urinary bladder resulting in frequent urination and / or pressure on the rectum causing constipation.

Large leiomyomata can press on the ureters (tubes going from the kidneys to the bladder) causing obstruction or blockage of urine which can lead to kidney damage.

Uterine leiomyomata also can cause infertility.

Previously, the only effective treatment for uterine leiomyomata was hysterectomy, an unacceptable treatment option for many women.

Myomectomy can be an effective treatment in some patients, however, there are risks associated with it.

Some of these risks include scarring and infection.

In some cases, scarring after myomectomy can lead to infertility.

However, uterine artery embolization may also have serious consequences including infection, massive uterine bleeding, and uterine necrosis, requiring emergency surgery.

Additionally, when the GnRH-agonist and a progesterone were co-administered, the expected regression of leiomyomata size seen with GnRH-agonist alone is not achieved.

Unfortunately, cessation of GnRH agonist treatment is followed by a rapid regrowth of uterine leiomyomata and of the uterus to pre-treatment volume.

Additionally, because bone health also requires estrogen, long term use of GnRH agonists can significantly decrease bone density and can lead to bone loss or osteoporosis.

Currently, therefore, use of GnRH agonists alone for treatment of uterine leiomyomata is usually limited to a short one to three month preoperative course to shrink the uterus to facilitate a surgical procedure or to induce amenorrhea to improve hematologic condition before surgery.

While these doses of mifepristone can help to treat uterine leiomyomata, there are problems associated with them.

For example, the highest described doses, such as 50 mg, can increase the prevalence and severity of hot flashes, can cause an elevation in hepatic enzymes and in some cases, due to mifepristone's antiglucocorticoid activity can result in deleterious side effects including, without limitation, glucocorticoid deprivation in the tissue and the pituitary gland resulting in an increase in serum ACTH and cortisol, as well as overt symptoms including complaints of anorexia, nausea, dizziness, weakness and somnolence.

While the lower described doses, such as 10 mg, can cause less severe drawbacks, these doses can still be associated with side effects such as increased hot flashes, potentially interfering with patient compliance.

Images